Evidence map›Paper›PMID 39672823›Full record

Trial reportPediatric research2025

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming.

James Peterson, Katherine Galarza, Siham Bchir, Celine Zocchetti, Isabelle Bertrand-Gerentes, Betzana Zambrano

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James PetersonJ. Lewis Research, Salt Lake City, UT, USA.
Katherine GalarzaScientific & Medical Affairs, Sanofi, Swiftwater, PA, USA.
Siham BchirGlobal Biostatistical Sciences, Sanofi, Marcy l'Étoile, France.
Celine ZocchettiGlobal Medical Affairs, Sanofi Lyon, France.
Isabelle Bertrand-GerentesGlobal Medical Affairs, Sanofi Lyon, France.
Betzana ZambranoGlobal Clinical Development Strategy, Sanofi, Montevideo, Uruguay. Betzana.Zambrano@sanofi.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

impactImmune persistence following primary vaccination with a single dose of meningococcal quadrivalent conjugate vaccines, MenACYW-TT/MCV4-CRM, at age 10-12 years was demonstrated. Most participants primed with MenACYW-TT and MCV4-CRM maintained seroprotective titers against all serogroups, suggesting continued protection. Priming with MenACYW-TT resulted in higher persistent titers for serogroups C, W, and Y than MCV4-CRM. A MenACYW-TT booster induced a robust immune response; almost all participants achieved seroprotection against all serogroups. This analysis supports the ACIP recommendations for routine administration of a primary dose of a meningococcal ACWY conjugate vaccine at 11-12 years, with a booster dose at 16 years.

Indexed as

Immunization, SecondaryMeningococcal InfectionsMeningococcal VaccinesAntibodies, BacterialChildFemaleHumansMaleNeisseria meningitidisSerogroupVaccinationVaccines, ConjugateAntibodies, BacterialMeningococcal Vaccinestetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccineVaccines, Conjugate

Identifiers

PMID39672823
PMCPMC12122353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.